DDInter484 DDInter1694
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Dasatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Dasatinib {u} (Compound) binds {v} (Gene) SRC
Dasatinib {u} (Compound) upregulates {v} (Gene) SATB1
Dasatinib {u} (Compound) downregulates {v} (Gene) EBNA1BP2
Dasatinib {u} (Compound) causes {v} (Side Effect) Body temperature increased
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Dasatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Granisetron
Dasatinib {u} may lead to a major life threatening interaction when taken with {v} Halofantrine
Dasatinib (Compound) treats hematologic cancer (Disease)
Dasatinib (Compound) binds SRC (Gene)
Dasatinib (Compound) upregulates SATB1 (Gene)
Dasatinib (Compound) downregulates EBNA1BP2 (Gene)
Dasatinib (Compound) causes Body temperature increased (Side Effect)
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Dasatinib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Dasatinib may lead to a major life threatening interaction when taken with Halofantrine